Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atomo DiagnosticsASX:AT1 EV-to-EBIT is -2.41 as of Jul. 27, 2026. The stock has 4 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Atomo Diagnostics ranks worse than 214592.06% on this metric.
The historical rank and industry rank for Atomo Diagnostics's EV-to-EBIT or its related term are showing as below:
ASX:AT1'
s EV-to-EBIT Range Over the Past 10 Years
Min: -33.33 Med: -3.04 Max: 0.12
Current: -2.41
During the past 6 years, the highest EV-to-EBIT of Atomo Diagnostics was 0.12. The lowest was -33.33. And the median was -3.04.
ASX:AT1's EV-to-EBIT is ranked worse than 100% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 18.395
vs ASX:AT1: -2.41
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Atomo Diagnostics's Enterprise Value for the quarter that ended in Dec. 2025 was A$26.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Atomo Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atomo Diagnostics EV-to-EBIT Related Terms
Atomo Diagnostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Atomo Diagnostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Atomo Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's EV-to-EBIT falls into.
Atomo Diagnostics's current Enterprise Value is A$12.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Atomo Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atomo Diagnostics (ASX:AT1) has a EV-to-EBIT of -2.41 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Atomo Diagnostics and its competitors. According to the industry distribution chart, Atomo Diagnostics ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is Atomo Diagnostics' EV-to-EBIT too high?
Atomo Diagnostics' current EV-to-EBIT is -2.41. Based on the distribution chart, Atomo Diagnostics ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Atomo Diagnostics' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #999999 out of 466 companies for EV-to-EBIT. This places Atomo Diagnostics in the lower half of its industry. The industry median EV-to-EBIT is 18.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Atomo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current EV-to-EBIT is -2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current EV-to-EBIT is -2.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current EV-to-EBIT is -2.41 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 
